Systemic therapy

Research output: Contribution to journalShort surveypeer-review

Abstract

New data continue to refine our knowledge of systemic therapy for breast cancer. These include the third Oxford Overview on adjuvant systemic therapy, a small advantage of anthracycline regimens over CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), and renewed interest in the 'classic CMF' regimen. Primary chemotherapy offers a greater chance of breast conservation (although no survival advantage), and tamoxifen also benefits women with noninvasive disease. New data are available on biphosphonates, ovarian ablation, anti-estrogens, anti-HER-2 (human epidermal growth factor receptor-2) antibody, and HER-2 expression as a predictive or prognostic factor. Early results of high-dose chemotherapy have been released, and the role of taxanes in early and advanced disease continues to expand. This article reviews these and other recent advances.

Original languageEnglish (US)
Pages (from-to)468-474
Number of pages7
JournalCurrent opinion in oncology
Volume11
Issue number6
DOIs
StatePublished - Nov 17 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Systemic therapy'. Together they form a unique fingerprint.

Cite this